Search Results for “ oncology” – Page 68 – media

Cancer Startup Torque Therapeutics Nabs $21 Million and Sets Up Shop in Kendall Square

Torque Therapeutics has come out of stealth mode to launch with a $21 million Series A financing. It is looking to raise another $14 million, according to its filing with the U.S. Securities and Exchange Commission (SEC).
- Source: Biospace
- 824
- September 15, 2017
cell immune Series therapy
Teva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental New Drug Application (sNDA) for the use of TRISENOX® (arsenic trioxide) injection in combination with all-trans retinoic acid (ATRA) for induction of remission and consolidation in patients with newly diagnosed low or intermediate risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
- Source: Tevapharm
- 567
- September 15, 2017
APL ATRA leukemia New Approvals TRISENOX
Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has entered into a definitive agreement under which CooperSurgical will acquire PARAGARD® (intrauterine copper contraceptive), a product within its global Women’s Health business, in a $1.1 billion cash transaction. PARAGARD® had revenues of approximately $168 million for the trailing twelve month period ending June 30, 2017. This transaction includes Teva’s manufacturing facility in Buffalo, NY, which produces PARAGARD® exclusively.
- Source: finance.yahoo
- 531
- September 13, 2017
Company Insight Market Views oncology PARAGARD
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53%

Novartis today announced results from a Phase III study of 870 patients with stage III BRAF V600E/K mutation-positive melanoma after complete surgical resection treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) .
- Source: Novartis
- 827
- September 13, 2017
Mekinist Phase Tafinlar
Bay Area’s ARMO BioSciences Banks $67 Million From Big Name Investors Like Celgene (CELG) And Google (GOOG)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the successful completion of a $67 million Series C-1 private financing. The Series C-1 proceeds will be used to initiate phase 2/3 studies with ARMO's lead immunotherapy agent AM0010 in non-small cell lung cancer(NSCLC) and renal cell cancer and to support an ongoing pivotal phase 3 clinical trial in advanced pancreatic cancer.
- Source: biospace
- 528
- September 13, 2017
immunotherapy Market Views NSCLC pancreatic renal Series
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise

Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose technology targets the retinoic acid-inducible gene I (RIG-I) pathway.
- Source: genengnews
- 542
- September 11, 2017
acquisition immunotherapy Market Views RIG-I
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for 8:30 AM EDT this morning; dial-in and webcast details are provided below.
- Source: Globenewswire
- 3,273
- September 11, 2017
cancer Company Insight T-cell
Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors

A collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T) (RELATED: Kite begins EU trial of CAR–T therapy) was announced by Takeda Pharmaceutical Company Limited (TSE: 4502) and Noile-Immune Biotech Inc..
- Source: Takeda
- 883
- September 6, 2017
antigen CAR–T Market Views receptor therapy
LabCorp completes $1.2B Chiltern buy

Diagnostics company LabCorp (NYSE:LH) said today that it has closed its $1.2 billion acquisition of contract research organization Chiltern International.
- Source: drugdeliverybusiness
- 667
- September 4, 2017
acquisition Clinical Market Views oncology
2nd International Conference on Pediatric Neurology

Pediatric Neurology 2017 will focus on the latest and exodus innovations in all areas of Pediatric neurology research which offers exclusive opportunity for investigators across the globe to meet, network, and perceive new scientific innovations. This year's annual congress highlights the theme, "Channelizing the novel ideas for treating Pediatric Neurological Disorders" which reflects the innovative progress in Pediatric Neurology research.
- Source: drugs
- 596
- September 1, 2017
Exhibitions & Activities Pediatric Neurology

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.